According to the Guojin Securities Research Report, the 2026 WCLC was held in Seoul, and innovative Chinese drugs were introduced intensively: Kangfang Iwasi's first-line NSCLC head-to-head Pabolizol, leading IO2.0 with PD-1/VEGF dual antibodies; Hanson/Yilian B7-H3 ADC entered the conference hall, and ADC migrated to the frontline + perioperative period; precision treatments such as KRAS G12D, HER2, and EGFR drug resistance broke through. China's dual antibody/ADC/small nucleic acid has global competitiveness and is leading the world in data. It is expected to catalyze a new round of overseas marketing of innovative drugs and revaluation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.